Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer’s disease

  • Miharu Samuraki
  • Ichiro MatsunariEmail author
  • Wei-Ping Chen
  • Kazuyoshi Yajima
  • Daisuke Yanase
  • Akihiko Fujikawa
  • Nozomi Takeda
  • Shintaro Nishimura
  • Hiroshi Matsuda
  • Masahito Yamada
Original Article



Although 18F-fluorodeoxyglucose (FDG) PET is an established imaging technique to assess brain glucose utilisation, accurate measurement of tracer concentration is confounded by the presence of partial volume effect (PVE) due to the limited spatial resolution of PET, which is particularly true in atrophic brains such as those encountered in patients with Alzheimer’s disease (AD). Our aim was to investigate the effects of PVE correction on FDG PET in conjunction with voxel-based morphometry (VBM) in patients with mild AD.


Thirty-nine AD patients and 73 controls underwent FDG PET and MRI. The PVE-corrected grey matter PET images were obtained using an MRI-based three-compartment method. Additionally, the results of PET were compared with grey matter loss detected by VBM.


Before PVE correction, reduced FDG uptake was observed in posterior cingulate gyri (PCG) and parieto-temporal lobes (PTL) in AD patients, which persisted after PVE correction. Notably, PVE correction revealed relatively preserved FDG uptake in hippocampal areas, despite the grey matter loss in medial temporal lobe (MTL) revealed by VBM.


FDG uptake in PCG and PTL is reduced in AD regardless of whether or not PVE correction is applied, supporting the notion that the reduced FDG uptake in these areas is not the result of atrophy. Furthermore, FDG uptake by grey matter tissue in the MTL, including hippocampal areas, is relatively preserved, suggesting that compensatory mechanisms may play a role in patients with mild AD.


Alzheimer’s disease FDG PVE Cortical atrophy Hippocampus 



This study was supported in part by a grant for Development of Advanced Technology for Measurement and Evaluation of Brain Functions, Ishikawa Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence (to S.N. and M.Y.), from Japan Science and Technology Corporation, Japan, and by a grant for the Knowledge Cluster Initiative [High-Tech Sensing and Knowledge Handling Technology (Brain Technology)] (to M.Y.) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan. The authors would like to thank Shigeo Hayashi and Masamichi Matsudaira of The Medical and Pharmacological Research Center Foundation for their technical support and the staff of the Department of Neurology of Kanazawa University Hospital for their clinical support.


  1. 1.
    Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94.PubMedCrossRefGoogle Scholar
  2. 2.
    Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Herholz K. PET studies in dementia. Ann Nucl Med 2003;17:79–89.PubMedCrossRefGoogle Scholar
  5. 5.
    Chen WP, Matsunari I, Noda A, Yanase D, Yajima K, Takeda N, et al. Rapid scanning protocol for brain 18F-FDG PET: a validation study. J Nucl Med 2005;46:1633–41.PubMedGoogle Scholar
  6. 6.
    Ibáñez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s disease. Neurology 1998;50:1585–93.PubMedGoogle Scholar
  7. 7.
    Matsuda H, Ohnishi T, Asada T, Li ZJ, Kanetaka H, Imabayashi E, et al. Correction for partial-volume effects on brain perfusion SPECT in healthy men. J Nucl Med 2003;44:1243–52.PubMedGoogle Scholar
  8. 8.
    Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging 2005;32:794–805.PubMedCrossRefGoogle Scholar
  9. 9.
    Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage 2000;11:805–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Pelletier D, Garrison K, Henry R. Measurement of whole-brain atrophy in multiple sclerosis. J Neuroimaging 2004;14:11S–9S.PubMedCrossRefGoogle Scholar
  11. 11.
    May A. The role of imaging in the pathophysiology and diagnosis of headache. Curr Opin Neurol 2005;18:293–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Karas GB, Burton EJ, Rombouts SA, van Schijndel RA, O’Brien JT, Scheltens P, et al. A comprehensive study of gray matter loss in patients with Alzheimer’s disease using optimized voxel-based morphometry. Neuroimage 2003;18:895–907.PubMedCrossRefGoogle Scholar
  13. 13.
    Ishii K, Sasaki H, Kono AK, Miyamoto N, Fukuda T, Mori E. Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2005;32:959–63.PubMedCrossRefGoogle Scholar
  14. 14.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.PubMedGoogle Scholar
  15. 15.
    Berg L. Clinical dementia rating. Br J Psychiatry 1984;145:339.PubMedGoogle Scholar
  16. 16.
    Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme Medical, 1988.Google Scholar
  17. 17.
    Frith CD, Friston K, Ashburner J, Holmes A, Poline J, Worsley K, et al. Principles and methods. In: Frackowiak RSJ, Friston KJ, Frith C, Dolan R, Mazziotta J, editors. Human brain function. San Diego: Academic; 1997. p. 3–159.Google Scholar
  18. 18.
    Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease. J Nucl Med 1997;38:925–8.PubMedGoogle Scholar
  19. 19.
    Soonawala D, Amin T, Ebmeier KP, Steele JD, Dougall NJ, Best J, et al. Statistical parametric mapping of 99mTc-HMPAO-SPECT images for the diagnosis of Alzheimer’s disease: normalizing to cerebellar tracer uptake. Neuroimage 2002;17:1193–202.PubMedCrossRefGoogle Scholar
  20. 20.
    Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14:21–36.PubMedCrossRefGoogle Scholar
  21. 21.
    Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer’s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47:454–61.PubMedGoogle Scholar
  22. 22.
    Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999;40:2053–65.PubMedGoogle Scholar
  23. 23.
    Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of 18F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001;42:548–57.PubMedGoogle Scholar
  24. 24.
    Ball MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol (Berl) 1977;37:111–8.CrossRefGoogle Scholar
  25. 25.
    Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Ball MJ, Fisman M, Hachinski V, Blume W, Fox A, Kral VA, et al. A new definition of Alzheimer’s disease: a hippocampal dementia. Lancet 1985;1:14–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Ouchi Y, Nobezawa S, Okada H, Yoshikawa E, Futatsubashi M, Kaneko M. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998;51:136–42.PubMedGoogle Scholar
  28. 28.
    De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529–39.PubMedCrossRefGoogle Scholar
  29. 29.
    Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005;64:1860–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Jagust WJ. Functional imaging patterns in Alzheimer’s disease. Relationships to neurobiology. Ann N Y Acad Sci 1996;777:30–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Relatively preserved hippocampal glucose metabolism in mild Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:317–22.PubMedCrossRefGoogle Scholar
  32. 32.
    Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486–510.PubMedCrossRefGoogle Scholar
  33. 33.
    Horwitz B. Neuroplasticity and the progression of Alzheimer’s disease. Int J Neurosci 1988;41:1–14.PubMedGoogle Scholar
  34. 34.
    Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease. J Neurol Sci 1987;78:151–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage 1995;2:148–56.PubMedCrossRefGoogle Scholar
  36. 36.
    Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer’s disease. Neurobiol Aging 1990;11:29–37.PubMedCrossRefGoogle Scholar
  37. 37.
    Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC, Chui HC. Plasticity of hippocampal circuitry in Alzheimer’s disease. Science 1985;230:1179–81.PubMedCrossRefGoogle Scholar
  38. 38.
    Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005;65:404–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Insausti R, Amaral DG, Cowan WM. The entorhinal cortex of the monkey: II. Cortical afferents. J Comp Neurol 1987;264:356–95.PubMedCrossRefGoogle Scholar
  40. 40.
    Munoz M, Insausti R. Cortical efferents of the entorhinal cortex and the adjacent parahippocampal region in the monkey (Macaca fascicularis). Eur J Neurosci 2005;22:1368–88.PubMedCrossRefGoogle Scholar
  41. 41.
    Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005;234:851–9.PubMedCrossRefGoogle Scholar
  42. 42.
    West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. Lancet 1994;344:769–72.PubMedCrossRefGoogle Scholar
  43. 43.
    Hof PR, Bussiere T, Gold G, Kovari E, Giannakopoulos P, Bouras C, et al. Stereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer disease. J Neuropathol Exp Neurol 2003;62:55–67.PubMedGoogle Scholar
  44. 44.
    Rasmusson DX, Brandt J, Steele C, Hedreen JC, Troncoso JC, Folstein MF. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord 1996;10:180–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003;226:315–36.PubMedCrossRefGoogle Scholar
  46. 46.
    Mosconi L, De Santi S, Li Y, Li J, Zhan J, Tsui WH, et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET. Eur J Nucl Med Mol Imaging 2006;33:210–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Miharu Samuraki
    • 1
  • Ichiro Matsunari
    • 2
    Email author
  • Wei-Ping Chen
    • 2
  • Kazuyoshi Yajima
    • 2
  • Daisuke Yanase
    • 1
  • Akihiko Fujikawa
    • 2
  • Nozomi Takeda
    • 2
  • Shintaro Nishimura
    • 2
  • Hiroshi Matsuda
    • 3
  • Masahito Yamada
    • 1
  1. 1.Department of Neurology and Neurobiology of AgingKanazawa University Graduate School of Medical ScienceKanazawaJapan
  2. 2.The Medical and Pharmacological Research Center FoundationHakui-CityJapan
  3. 3.Department of Nuclear MedicineSaitama Medical School HospitalSaitamaJapan

Personalised recommendations